Martine A. Rothblatt Sells 7,054 Shares of United Therapeutics Co. (UTHR) Stock
United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 7,054 shares of the business’s stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $113.16, for a total transaction of $798,230.64. Following the sale, the chief executive officer now directly owns 7,195 shares of the company’s stock, valued at approximately $814,186.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of United Therapeutics stock opened at $114.28 on Friday. The firm has a market capitalization of $4.89 billion, a P/E ratio of 10.49, a PEG ratio of 42.29 and a beta of 1.12. The company has a quick ratio of 4.05, a current ratio of 4.32 and a debt-to-equity ratio of 0.09. United Therapeutics Co. has a fifty-two week low of $100.06 and a fifty-two week high of $147.18.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing the consensus estimate of $3.23 by ($0.81). The firm had revenue of $412.70 million during the quarter, compared to the consensus estimate of $378.22 million. United Therapeutics had a return on equity of 25.24% and a net margin of 31.73%. The company’s quarterly revenue was down 7.4% on a year-over-year basis. During the same period in the prior year, the company posted $4.69 EPS. On average, sell-side analysts forecast that United Therapeutics Co. will post 14.28 EPS for the current year.
A number of brokerages have recently issued reports on UTHR. BidaskClub raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 17th. Wedbush set a $253.00 target price on shares of United Therapeutics and gave the stock a “buy” rating in a report on Thursday, September 27th. Zacks Investment Research downgraded shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 22nd. Standpoint Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 12th. Finally, Credit Suisse Group upped their target price on shares of United Therapeutics from $103.00 to $105.00 and gave the stock a “sell” rating in a report on Monday, November 19th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $134.00.
ILLEGAL ACTIVITY WARNING: This report was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://theolympiareport.com/2019/01/11/martine-a-rothblatt-sells-7054-shares-of-united-therapeutics-co-uthr-stock.html.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Article: What is net income?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.